Adam Feuerstein, who has covered biotech companies for TheStreet.com for most of the past 15 years, resigned on Monday to accept a job at STAT.
He will also cover biotech for STAT, which is owned by the Boston Globe and covers health care news, as a national biotech columnist. He starts June 19.
“As for STAT, I first met Rick Berke almost two years ago, exactly,” said Feuerstein in an email to Talking Biz News. “I’ve followed the site’s progress and been impressed with the work they’ve published. They’re kicking ass and my goal is to help them kick more ass. Berke’s pitch to me was ‘We want Adam to be Adam,’ so that’s what I’ll do, continue covering biotech from an investors’ perspective with the same ferocity and no-holds-barred honesty that I’ve been doing for the past 15 years.”
A STAT story one year ago said Feuerstein may “be the most feared journalist covering the biotech industry. He digs deep into the science to take down companies that he believes overhype their drugs, distort their data, or make ridiculously grandiose promises.”
“I worked alongside so many talented reporters and editors there,” said Feuerstein about TheStreet. “I learned something from all of them, and they helped me become a better reporter. TheStreet is a permanent part of my DNA, and I will always be a proud and appreciative alumnus of this place.
“Working for and alongside Jim Cramer all these years has been an honor,” he added. “He taught me so much about Wall Street and journalism. I cannot thank him enough.”
